Literature DB >> 29075955

Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices.

Renzo Y Loyaga-Rendon1, Milena Jani2, David Fermin2, Jennifer K McDermott2, Diane Vancamp2, Sangjin Lee2.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to describe the current knowledge in prevention and treatment of thrombotic (pump thrombosis and ischemic stroke) and bleeding (gastrointestinal and hemorrhagic stroke) complications in patients supported by continuous-flow left ventricular assist devices (CF-LVAD). RECENT
FINDINGS: Left ventricular assist devices (LVADs) are now widely used for the management of end-stage heart failure. Unfortunately, in spite of the indisputable positive impact LVADs have on patients, the frequency and severity of complications are limitations of this therapy. Stroke, pump thrombosis, and gastrointestinal bleeding are among the most serious and frequent complications in these patients. The balance between hemorrhagic and thrombotic complications in patients supported with CF-LVAD is difficult as most patients do not necessarily fit a "bleeder" or a "clotter" profile but rather move from one side to the other of the thrombotic/bleeding spectrum. Further research is necessary to better understand the risk factors and mechanisms involved in the development of these complications.

Entities:  

Keywords:  Bleeding; Complications; LVAD; Prevention; Stroke; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 29075955     DOI: 10.1007/s11897-017-0367-3

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  92 in total

1.  The hemodynamic effects of the LVAD outflow cannula location on the thrombi distribution in the aorta: A primary numerical study.

Authors:  Yage Zhang; Bin Gao; Chang Yu
Journal:  Comput Methods Programs Biomed       Date:  2016-06-07       Impact factor: 5.428

2.  Treatment of device thrombus in the HeartWare HVAD: Success and outcomes depend significantly on the initial treatment strategy.

Authors:  John M Stulak; Shannon M Dunlay; Shashank Sharma; Nicholas A Haglund; Mary Beth Davis; Jennifer Cowger; Palak Shah; Faraz Masood; Keith D Aaronson; Francis D Pagani; Simon Maltais
Journal:  J Heart Lung Transplant       Date:  2015-12       Impact factor: 10.247

3.  Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).

Authors:  Randall C Starling; Yoshifumi Naka; Andrew J Boyle; Gonzalo Gonzalez-Stawinski; Ranjit John; Ulrich Jorde; Stuart D Russell; John V Conte; Keith D Aaronson; Edwin C McGee; William G Cotts; David DeNofrio; Duc Thinh Pham; David J Farrar; Francis D Pagani
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

4.  Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices.

Authors:  Jennifer A Frontera; Randall Starling; Sung-Min Cho; Amy S Nowacki; Ken Uchino; M Shazam Hussain; Maria Mountis; Nader Moazami
Journal:  J Heart Lung Transplant       Date:  2016-12-23       Impact factor: 10.247

5.  Unexpected abrupt increase in left ventricular assist device thrombosis.

Authors:  Randall C Starling; Nader Moazami; Scott C Silvestry; Gregory Ewald; Joseph G Rogers; Carmelo A Milano; J Eduardo Rame; Michael A Acker; Eugene H Blackstone; John Ehrlinger; Lucy Thuita; Maria M Mountis; Edward G Soltesz; Bruce W Lytle; Nicholas G Smedira
Journal:  N Engl J Med       Date:  2013-11-27       Impact factor: 91.245

6.  Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Left Ventricular Assist Devices.

Authors:  Christopher T Sparrow; Michael E Nassif; David S Raymer; Eric Novak; Shane J LaRue; Joel D Schilling
Journal:  JACC Heart Fail       Date:  2015-11-11       Impact factor: 12.035

7.  Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices.

Authors:  Kelly Schlendorf; Chetan B Patel; Thomas Gehrig; Todd L Kiefer; G Michael Felker; Adrian F Hernandez; Laura J Blue; Carmelo A Milano; Joseph G Rogers
Journal:  J Card Fail       Date:  2013-12-18       Impact factor: 5.712

8.  Gastrointestinal Bleeding during Continuous-Flow Left Ventricular Assist Device Support is Associated with Lower Rates of Cardiac Transplantation.

Authors:  Christopher T Holley; Laura Harvey; Samit S Roy; Rebecca Cogswell; Peter Eckman; Kenneth Liao; Ranjit John
Journal:  ASAIO J       Date:  2015 Nov-Dec       Impact factor: 2.872

9.  Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality.

Authors:  Nader Moazami; Carmelo A Milano; Ranjit John; Benjamin Sun; Robert M Adamson; Francis D Pagani; Nicholas Smedira; Mark S Slaughter; David J Farrar; O Howard Frazier
Journal:  Ann Thorac Surg       Date:  2012-12-20       Impact factor: 4.330

10.  Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience.

Authors:  Ronald M Lazar; Peter A Shapiro; Brian E Jaski; Michael K Parides; Robert C Bourge; John T Watson; Laura Damme; Walter Dembitsky; Jeffrey D Hosenpud; Lopa Gupta; Anita Tierney; Tonya Kraus; Yoshifumi Naka
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

View more
  1 in total

1.  Prevalence and management of driveline infections in mechanical circulatory support - a single center analysis.

Authors:  Tomasz Dziodzio; Mariusz Kuśmierczyk; Andrzej Juraszek; Mikołaj Smólski; Piotr Kołsut; Jarosław Szymański; Paweł Litwiński; Krzysztof Kuśmierski; Joanna Zakrzewska-Koperska; Maciej Sterliński
Journal:  J Cardiothorac Surg       Date:  2021-08-03       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.